Zymeworks Inc. is a clinical-stage biotechnology company that discovers, develops, and commercializes biotherapeutics for the treatment of cancer, as well as autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates.
The company's platforms include the Azymetric multispecific antibody platform; the Drug Conjugate platform, which includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; the EFECT platform, which consists of a set of modifications to the Fc region of antibodies that enable the selective modulation of recruited cytotoxic immune cells for various therapeutic applications; and ProTECT, a tumor-specific immune co-stimulation platform.
Its lead product candidate is zanidatamab, a novel bispecific antibody that targets human epidermal growth factor receptor 2 (HER2) and is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials. Additionally, zanidatamab zovodotin, a HER2-targeted antibody-drug conjugate, is in Phase 2 clinical trials for the treatment of advanced or metastatic HER2-expressing tumors.
In addition, the company develops a pipeline of preclinical product candidates. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc.
Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
